HIV‐1 Non Group‐M Phenotypic Susceptibility to Ibalizumab
> 10 000 ng/mL; MPI < 25%). Interpretable results were not obtained for 4 HIV-1/O and 1 HIV-1/N strains under standardization criteria. PNGS numbers in the V5 loop ranged from 0 to 4 in tested isolates. Ibalizumab showed in vitro activity against all validated HIV-1/O and HIV-1/N isolates, whereas the HIV-1/P strain exhibited potential natural resistance. No relationship was observed between PNGS number and susceptibility.
Authors
- Jean‐Christophe Plantier (ORCID: https://orcid.org/0000-0001-6417-4083)
- Élodie Alessandri-Gradt (ORCID: https://orcid.org/0000-0002-8906-3416)
- Fanny Lermechain
- Fabienne Tombette
- Henri Jullien
- Lucie Poisson (ORCID: https://orcid.org/0009-0009-5794-2131)
Institutions
- Délégation Paris 5 (FR)
- Inserm (FR)
- Université Paris Cité (FR)
- Sorbonne Paris Cité (FR)
- Normandie Université (FR)
- Hôpital Bichat-Claude-Bernard (FR)
- Centre Hospitalier Universitaire de Rouen (FR)
- Theratechnologies (Canada) (CA)
- Université de Rouen Normandie (FR)
Publication Details
- Journal
- Journal of Medical Virology
- Published
- 2026-04-01
- DOI
- https://doi.org/10.1002/jmv.70911
- Primary Topic
- HIV Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00